Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (1033)	7/8/1999 12:23:00 AM
From: Gary Mohilner	Respond to of 1073

After Phase 1 SmithKlein Beecham has the responsibility for the remainder of the trail, additionally IMGN will get $40 million + as milestones are met. Add $30 million from BioChem Pharma next year and they should be able to operate for many years and get into Phase 2 trials on N901-DC1 if the results of their Phase 1 trial goes well, this drug is for Small Cell Lung Cancer and should be in trials early next year. As the Tumor Activated Prodrug (TAP) technology proves itself, money should be no problem for the company. If C242-DM1 has problems in Phase 1, which is highly unlikely as it's been extensively tested in primates, the company should have funding sufficient to operate for at least a few years, not counting the $30 million. Gary